Souro Chowdhury

Opinion author

Souro Chowdhury, PhD, is a senior business analyst at Lifescience Dynamics with over five years of experience in drug development. He holds a PhD in chemical biology from Imperial College London. Chowdhury’s work spans oncology, rare nephrology and immunology, where he partners with biopharma clients on competitive intelligence, market research and strategic decision-making.

Opinion

The real potential of PD-(L)1×VEGF bispecifics may be outside lung cancer

PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing through trials in lung cancer. But the potential of these drugs may be highest in cancers where angiogenesis and immune escape are tightly intertwined.

May 28, 2026

6 min read

Souro Chowdhury